碘-125粒子植入治疗前列腺癌。5年及10年随访。

Iodine 125 seed implants for prostatic carcinoma. Five- and ten-year follow-up.

作者信息

Weyrich T P, Kandzari S J, Jain P R

机构信息

Department of Urology, West Virginia University Medical Center, Morgantown.

出版信息

Urology. 1993 Feb;41(2):122-6. doi: 10.1016/0090-4295(93)90160-c.

DOI:10.1016/0090-4295(93)90160-c

PMID:8497980

Abstract

Between 1975 and 1985 132 patients underwent bilateral pelvic lymphadenectomy and insertion of Iodine 125 seeds for biopsy-proved localized carcinoma of the prostate. Surgical stages were A2 9 percent, B 64 percent, C 9 percent, and D1 18 percent. Operative mortality was zero. Short and long-term complications were less than 33 percent. Ten-year survival rates of evaluable patients for surgical Stages A2, B1, B2, and C1 were 75 percent, 70 percent, 48 percent, and 44 percent, respectively. For these patients, ten-year disease-free rates for Stages A2, B1, B2, and C1 were 67 percent, 36 percent, 60 percent, and 25 percent, respectively. Interstitial radiotherapy may play a role in the treatment of nonsurgical candidates with low volume and well- to moderately-differentiated adenocarcinoma of the prostate.

摘要

1975年至1985年间，132例经活检证实为局限性前列腺癌的患者接受了双侧盆腔淋巴结清扫术并植入碘125粒子。手术分期为A2期占9%，B期占64%，C期占9%，D1期占18%。手术死亡率为零。短期和长期并发症发生率低于33%。手术分期为A2、B1、B2和C1期的可评估患者的十年生存率分别为75%、70%、48%和44%。对于这些患者，A2、B1、B2和C1期的十年无病生存率分别为67%、36%、60%和25%。间质放疗可能在治疗前列腺体积小且分化良好至中等的非手术候选腺癌患者中发挥作用。